In addition to promoting increased lymphocytic infiltration into the TME, TPST-1495 treatment also resulted in an increase in the numbers of XCR1+ DC1 cross-presenting dendritic cells, as a proportion of total cells within the tumor (Fig. 4G). Here, XCR1 is linked to neoplasm.